These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 3839156)

  • 1. Chemohormonal therapy and endocrine function in breast cancer patients.
    Dnistrian AM; Greenberg EJ; Dillon HJ; Hakes TB; Fracchia AA; Schwartz MK
    Cancer; 1985 Jul; 56(1):63-70. PubMed ID: 3839156
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adjuvant CMFVP versus tamoxifen versus concurrent CMFVP and tamoxifen for postmenopausal, node-positive, and estrogen receptor-positive breast cancer patients: a Southwest Oncology Group study.
    Rivkin SE; Green S; Metch B; Cruz AB; Abeloff MD; Jewell WR; Costanzi JJ; Farrar WB; Minton JP; Osborne CK
    J Clin Oncol; 1994 Oct; 12(10):2078-85. PubMed ID: 7931477
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Endocrine function in premenopausal and postmenopausal advanced breast cancer patients treated with CMF or tamoxifen.
    Bhatavdekar JM; Shah NG; Patel DD; Karelia NH; Trivedi SN; Vora HH; Ghosh N; Giri DD; Balar DB
    Neoplasma; 1992; 39(2):123-7. PubMed ID: 1528310
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjuvant chemohormonal therapy with cyclophosphamide, methotrexate, 5-fluorouracil, and prednisone (CMFP) or CMFP plus tamoxifen compared with CMF for premenopausal breast cancer patients. An Eastern Cooperative Oncology Group trial.
    Tormey DC; Gray R; Gilchrist K; Grage T; Carbone PP; Wolter J; Woll JE; Cummings FJ
    Cancer; 1990 Jan; 65(2):200-6. PubMed ID: 2403834
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of adjuvant chemohormonal therapy on the ovarian and adrenal function of breast cancer patients.
    Rose DP; Davis TE
    Cancer Res; 1980 Nov; 40(11):4043-7. PubMed ID: 6451282
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adjuvant chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil, vincristine, and prednisone compared with single-agent L-phenylalanine mustard for patients with operable breast carcinoma and positive axillary lymph nodes: 20-year results of a Southwest Oncology Group study.
    Rivkin SE; Green SJ; Lew D; Costanzi JJ; Athens JW; Osborne CK; Vaughn CB; Martino S
    Cancer; 2003 Jan; 97(1):21-9. PubMed ID: 12491501
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Endocrine versus endocrine plus five-drug chemotherapy in postmenopausal women with stage II estrogen receptor-positive breast cancer.
    Pearson OH; Hubay CA; Gordon NH; Marshall JS; Crowe JP; Arafah BM; McGuire W
    Cancer; 1989 Nov; 64(9):1819-23. PubMed ID: 2790695
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjuvant treatment for early breast cancer: the Ludwig breast cancer studies.
    Goldhirsch A; Gelber R
    NCI Monogr; 1986; (1):55-70. PubMed ID: 3774016
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adjuvant CMFVP versus adjuvant CMFVP plus ovariectomy for premenopausal, node-positive, and estrogen receptor-positive breast cancer patients: a Southwest Oncology Group study.
    Rivkin SE; Green S; O'Sullivan J; Cruz AB; Abeloff MD; Jewell WR; Costanzi JJ; Farrar WB; Osborne CK
    J Clin Oncol; 1996 Jan; 14(1):46-51. PubMed ID: 8558219
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparison of intermittent vs. continuous and of adriamycin vs. methotrexate 5-drug chemotherapy for advanced breast cancer. A Cancer and Leukemia Group B study.
    Tormey DC; Weinberg VE; Leone LA; Glidewell OJ; Perloff M; Kennedy BJ; Cortes E; Silver RT; Weiss RB; Aisner J
    Am J Clin Oncol; 1984 Jun; 7(3):231-9. PubMed ID: 6375344
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Endocrine effects of adjuvant chemotherapy and long-term tamoxifen administration on node-positive patients with breast cancer.
    Jordan VC; Fritz NF; Tormey DC
    Cancer Res; 1987 Jan; 47(2):624-30. PubMed ID: 3098415
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized trial comparing 12 weeks versus 36 weeks of adjuvant chemotherapy in stage II breast cancer.
    Levine MN; Gent M; Hryniuk WM; Bramwell V; Abu-Zahra H; DePauw S; Arnold A; Findlay B; Levin L; Skillings J
    J Clin Oncol; 1990 Jul; 8(7):1217-25. PubMed ID: 2193119
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preoperative chemotherapy in primarily inoperable cancer of the breast.
    Luboinski G; Nagadowska M; Pienkowski T
    Eur J Surg Oncol; 1991 Dec; 17(6):603-7. PubMed ID: 1743309
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Postsurgical adjuvant chemotherapy of stage II breast carcinoma with or without crossover to a non-cross-resistant regimen: a Cancer and Leukemia Group B study.
    Perloff M; Norton L; Korzun AH; Wood WC; Carey RW; Gottlieb A; Aust JC; Bank A; Silver RT; Saleh F; Canellos GP; Perry MC; Weiss RB; Holland JF
    J Clin Oncol; 1996 May; 14(5):1589-98. PubMed ID: 8622076
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Postoperative chemotherapy and chemohormonal therapy in women with node-positive breast cancer.
    Tormey DC; Gray R; Taylor SG; Knuiman M; Olson JE; Cummings FJ
    NCI Monogr; 1986; (1):75-80. PubMed ID: 3534593
    [TBL] [Abstract][Full Text] [Related]  

  • 16. One versus 2 years of CMFVP adjuvant chemotherapy in axillary node-positive and estrogen receptor-negative patients: a Southwest Oncology Group study.
    Rivkin SE; Green S; Metch B; Jewell WR; Costanzi JJ; Altman SJ; Minton JP; O'Bryan RM; Osborne CK
    J Clin Oncol; 1993 Sep; 11(9):1710-6. PubMed ID: 8355037
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjuvant CMFVP versus melphalan for operable breast cancer with positive axillary nodes: 10-year results of a Southwest Oncology Group Study.
    Rivkin SE; Green S; Metch B; Glucksberg H; Gad-el-Mawla N; Constanzi JJ; Hoogstraten B; Athens J; Maloney T; Osborne CK
    J Clin Oncol; 1989 Sep; 7(9):1229-38. PubMed ID: 2671283
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of systemic adjuvant chemotherapy on local breast recurrence in node positive breast cancer patients treated by lumpectomy without radiation.
    Levine MN; Bramwell V; Abu-Zahra H; Goodyear MD; Arnold A; Findlay B; Skillings J; Gent M
    Br J Cancer; 1992 Jan; 65(1):130-2. PubMed ID: 1733435
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adjuvant chemo-endocrine therapy in postmenopausal women with breast cancer and axillary-node metastases.
    Goldhirsch A; Castiglione M; Gelber RD
    Lancet; 1990 May; 335(8697):1099-100. PubMed ID: 1970400
    [No Abstract]   [Full Text] [Related]  

  • 20. Management of breast cancer.
    Cohen IA; Keller JH; Abate MA
    Clin Pharm; 1982; 1(6):515-29. PubMed ID: 6192963
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.